TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11570021

Group type: EXPERIMENTAL
Intervention: Sibutramine (20 mg/d)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 9725754

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.026 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lorazepam (both dosages)
Number of subjects: 36
Study: 7978471

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 40 mg.kg‐1 infused over 60 min after induction of anesthesia and 4 h later
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no DCA)
Number of subjects: 66
Study: 2568015

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antacids in very high doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prokinetic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antacids, antacid/alginate, metoclopramide, domperidone
Number of subjects: 0
Study: 29391346

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 786

Group type: COMPARATOR
Intervention: No atrial fibrillation (AF)
Number of subjects: 786
Study: 28768528

Group type: EXPERIMENTAL
Intervention: MPC + HA group (75 million allogeneic mesenchymal precursor cells suspended in hyaluronan)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MPC + HA group
Number of subjects: 17

Group type: COMPARATOR
Intervention: HA group (control)
Number of subjects: 17
Study: 26168497

Group type: EXPERIMENTAL
Intervention: Aprepitant (Group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 23
Study: 24621976

Group type: EXPERIMENTAL
Intervention: urocortin-2 infusion (5 ng/kg/min for 4 hours)
Number of subjects: 53

Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 53
Study: 21138861

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study: 18340390

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) with long-acting diltiazem (240 mg/day)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard office-based management (Control group)
Number of subjects: 270
Study: 17154747

Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both treatments (IBCT and TBCT)
Number of subjects: 130
Study: 12665170

Group type: EXPERIMENTAL
Intervention: Interactive Educational Videotaped Interventions (IEVI)
Number of subjects: 0
Study: 9656540

Group type: COMPARATOR
Intervention: Lactose free formula with higher levels of calcium (FSL)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Standard starting formula (FI)
Number of subjects: 19
Study: 7642086

Group type: EXPERIMENTAL
Intervention: Untreated ALL patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bone marrow cell nuclei in untreated ALL patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Children in remission from ALL
Number of subjects: 36
Study: 2753374

Group type: EXPERIMENTAL
Intervention: Formal respite care
Number of subjects: 642
Study: 596287

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 gm of alcohol/kg body weight)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (0.05 gm/kg)
Number of subjects: 14
Study: 31188778

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), 9 individual sessions (weekly one session)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 27837036

Group type: EXPERIMENTAL
Intervention: Enhanced homestead food production (EHFP) program consisting of home garden, poultry raising, and nutrition education implemented over 2.5 years
Number of subjects: 2106

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 2106
Study: 24286408

Group type: EXPERIMENTAL
Intervention: NPPV treatment group (NPPV group)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional treatment group (control group)
Number of subjects: 95
Study: 20924751

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alcohol clamp (blood alcohol concentration = 0.6‰)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MDMA + THC (inhalation of 4, 6 and 6 mg, interval of 1.5 h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19364364

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17567341

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% with 75 microg fentanyl (1.5 ml)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Levobupivacaine 0.5% with 1.5 ml saline
Number of subjects: 112
Study: 15142216

Group type: EXPERIMENTAL
Intervention: High-volume evacuation (HVE)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional dental suction (CDS)
Number of subjects: 6
Study: 11359492

Group type: EXPERIMENTAL
Intervention: SPIPN dressing
Number of subjects: 20
Study: 9828549

Group type: EXPERIMENTAL
Intervention: Neonates born to mothers with pre‐eclamptic toxaemia (PET)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Neonates born to mothers with normal conditions
Number of subjects: 90
Study: 7927233

Group type: EXPERIMENTAL
Intervention: Tc‐galactosyl‐neoglycoalbumin (radiolabeled asialoglycoprotein analog)
Number of subjects: 85
Study: 2913129

Group type: EXPERIMENTAL
Intervention: MC immunotherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo immunotherapy
Number of subjects: 14
Study: 328108

Group type: EXPERIMENTAL
Intervention: naloxone 40 microgram
Number of subjects: 0

Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 0
Study: 31540867

Group type: EXPERIMENTAL
Intervention: Semaglutide 1·0 mg once weekly
Number of subjects: 788

Group type: COMPARATOR
Intervention: Canagliflozin 300 mg once daily
Number of subjects: 788
Study: 29065390

Group type: EXPERIMENTAL
Intervention: Adapted treatment
Number of subjects: 227
Study: 25751232

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (partial pressure of carbon dioxide: 60 to 70 mmHg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Air
Number of subjects: 50
Study: 23104320

Group type: EXPERIMENTAL
Intervention: Bupivacaine (10 cc of 0.5% bupivacaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (10 cc of normal saline)
Number of subjects: 60
Study: 21325108

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g ethanol/kg body mass; n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g ethanol/kg body mass) during progressive LBNP
Number of subjects: 30
Study: 19249634

Group type: EXPERIMENTAL
Intervention: Fampridine (10 mg twice daily; n=229)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo (n=72)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Fampridine
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 16717292

Group type: EXPERIMENTAL
Intervention: Conventional sibling bone marrow transplantation (CBMT)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Alternative donor bone marrow transplantation (ABMT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: CBMT
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: ABMT
Number of subjects: 214

Group type: COMPARATOR
Intervention: CT
Number of subjects: 214
Study: 16600233

Group type: EXPERIMENTAL
Intervention: Polymorphisms of peroxisome proliferator-activated receptor-gamma (Pro12Ala)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Polymorphisms of peroxisome proliferator-activated receptor-coactivator-1 (Gly482Ser)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Body mass index and reproductive hormones among various genotypic groups of PCOS
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (147 regularly cycling women)
Number of subjects: 201
Study: 12707979

Group type: EXPERIMENTAL
Intervention: Volitionally induced responses (V)
Number of subjects: 50
Study: 10337295

Group type: EXPERIMENTAL
Intervention: Silux Plus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Z100
Number of subjects: 30
Study: 8588686

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms bd via Diskhaler (n = 121)
Number of subjects: 243
Study: 2149648

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168
Study: 6775561

Group type: EXPERIMENTAL
Intervention: Naloxone (15 mg, intravenously)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline solution (equivalent volume to naloxone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg, intravenously)
Number of subjects: 6
Study: 30710837

Group type: EXPERIMENTAL
Intervention: E + cPTH
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: E + iPTH
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: E
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 28781171

Group type: EXPERIMENTAL
Intervention: FOLFOX plus SIRT
Number of subjects: 1103

Group type: COMPARATOR
Intervention: FOLFOX alone
Number of subjects: 1103
Study: 26439944

Group type: EXPERIMENTAL
Intervention: Levodopa infusion
Number of subjects: 11
Study: 24429275

Group type: EXPERIMENTAL
Intervention: RPL554 (0.009 mg/kg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: RPL554 (0.018 mg/kg)
Number of subjects: 57
Study: 21334654

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 127

Group type: COMPARATOR
Intervention: Tension-free vaginal tape-obturator
Number of subjects: 127
Study: 19334042

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 20
Study: 17284917

Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste directly after erosion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste 2 hours after erosion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste before erosion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Brushing with fluoride toothpaste
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Brushing with fluoride toothpaste or gel, and rinsing with a fluoride mouth rinse
Number of subjects: 5

Group type: COMPARATOR
Intervention: Erosion only (no brushing)
Number of subjects: 5
Study: 14754644

Group type: EXPERIMENTAL
Intervention: 1% coal tar lotion (Exorex)
Number of subjects: 324

Group type: COMPARATOR
Intervention: 5% conventional coal tar lotion (Alphosyl)
Number of subjects: 324
Study: 11359890

Group type: EXPERIMENTAL
Intervention: Lateral intermetatarsal angle measurement in hallux limitus feet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lateral intermetatarsal angle measurement in normal feet
Number of subjects: 60
Study: 10322856

Group type: EXPERIMENTAL
Intervention: Yizhi capsule (YZC), 4 capsules each time, three times a day for two months
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Yizhi capsule (YZC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hydergine, 2 mg each time, three times a day for two months
Number of subjects: 61
Study: 8490153

Group type: EXPERIMENTAL
Intervention: Fast-spin-echo sequences (FSE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional spin-echo sequences (CSE)
Number of subjects: 20
Study: 3449477

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (6,000 rad)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Preoperative radiation therapy (5,000 rad)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Definitive radiation therapy (6,500‐7,000 rad)
Number of subjects: 320
Study: 31344699

Group type: EXPERIMENTAL
Intervention: Telephone-based physician-investigator driven enrollment method
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Self-consent
Number of subjects: 1700

Group type: COMPARATOR
Intervention: LAR (Legally Authorized Representative) consent
Number of subjects: 1700

Group type: COMPARATOR
Intervention: EFIC (Exception from Informed Consent)
Number of subjects: 1700
Study: 28696380

Group type: EXPERIMENTAL
Intervention: Whey protein (25 g of MuscleTech 100% Whey)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Energy-matched placebo (CHO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rested control trial (no exercise, no supplement)
Number of subjects: 12
Study: 24611590

Group type: EXPERIMENTAL
Intervention: Lokomat therapy combined with conventional therapy (twice a week Lokomat + three times 30 min conventional therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional assisted overground therapy only (3.5 h a week)
Number of subjects: 30
Study: 23816026

Group type: EXPERIMENTAL
Intervention: Overlapping drug-eluting stents (DESs)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nonoverlapping drug-eluting stents (DESs)
Number of subjects: 31
Study: 21441148

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study: 20104414

Group type: EXPERIMENTAL
Intervention: Evidence-based supported employment
Number of subjects: 301

Group type: COMPARATOR
Intervention: Conventional vocational rehabilitation (standard care)
Number of subjects: 301
Study: 16942557

Group type: EXPERIMENTAL
Intervention: Structured Histories (SH)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Unstructured History (USH)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Computer Database (CD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Unstructured History (USH) and Structured Histories (SH)
Number of subjects: 43
Study: 15225178

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/day
Number of subjects: 179
Study: 12479619

Group type: EXPERIMENTAL
Intervention: Visual feedback balance training with the SMART Balance Master
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 9717526

Group type: EXPERIMENTAL
Intervention: Embolization
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 45
Study: 8122957

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.1 mg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2521863

Group type: EXPERIMENTAL
Intervention: CV 205-502 (0.01-0.05 mg initially, increased to 0.03-0.09 mg at 12 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CV 205-502
Number of subjects: 26
Study: 9883

Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisucccinate (150 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Methyl prednisolone sulfate (30 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Prednisone sodium m sulfobenzoate (50 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Prednisolone sodium m sulfobenzoate (35 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate (2 mg and 6 mg/kg)
Number of subjects: 61
Study: 30094650

Group type: EXPERIMENTAL
Intervention: Tetric N‐Bond Self‐Etch (TN; Ivoclar/Vivadent, Liechtenstein)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond 2 adhesive (SE; Kuraray Noritake Dental Inc, Japan)
Number of subjects: 20
Study: 28530433

Group type: COMPARATOR
Intervention: Multilevel intervention aimed at improving mental health of PLH and their family members.
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Multilevel intervention for PLH.
Number of subjects: 997

Group type: COMPARATOR
Intervention: Control condition (no intervention).
Number of subjects: 997
Study: 25652389

Group type: EXPERIMENTAL
Intervention: Insulin deficiency (fasting C-peptide ≤0.15 nmol/l)
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: Presence of IAA autoantibodies or baseline insulin use
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: GAD autoantibodies
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: IA2 autoantibodies
Number of subjects: 1401

Group type: EXPERIMENTAL
Intervention: ZnT8 autoantibodies
Number of subjects: 1401
Study: 24400383

Group type: EXPERIMENTAL
Intervention: Meglumine acridonacetate
Number of subjects: 100
Study: 22021253

Group type: EXPERIMENTAL
Intervention: Approach motivation (reward for navigating to correct locations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoidance motivation (punishment for navigating to incorrect platforms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmotivated spatial learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High arousal during approach motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High arousal across subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-performing, highly aroused participants
Number of subjects: 0
Study: 19222404

Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dim light therapy
Number of subjects: 63
Study: 17117070

Group type: EXPERIMENTAL
Intervention: 3D‐SSP z‐score maps
Number of subjects: 315

Group type: COMPARATOR
Intervention: Standard transaxial section displays
Number of subjects: 315
Study: 15097308

Group type: EXPERIMENTAL
Intervention: 60 mg of elemental iron given twice weekly for four months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of iron (not specified)
Number of subjects: 0
Study: 10762511

Group type: EXPERIMENTAL
Intervention: Active p42MAPK expression in s‐IBM
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Western blot analysis of cell lysates
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Immunocytochemistry using antibodies against phosphoepitopes
Number of subjects: 7

Group type: COMPARATOR
Intervention: Disease controls (N=15)
Number of subjects: 7
Study: 8614771

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stress Management Treatment (SMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 60
Study: 1466618

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) 0.1 mg/kg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6704272

Group type: EXPERIMENTAL
Intervention: Extradural morphine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Extradural bupivacaine (0.5%)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional i.v. morphine (control)
Number of subjects: 3
Study: 31029230

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1085
Study: 28809628

Group type: EXPERIMENTAL
Intervention: Shoulder girdle muscles activation during wrist immobilization (group I, n=20, mean age 59.8 years)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard rehabilitation (group II, n=20, mean age 61.3 years)
Number of subjects: 40
Study: 24652598

Group type: EXPERIMENTAL
Intervention: Multi-professional treatment within a clinical pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23244640

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) - self-monitoring negative thoughts five times daily for 2 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Non-EMA control group - did not self-monitor negative thoughts
Number of subjects: 117
Study: 21795983

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 19467543

Group type: EXPERIMENTAL
Intervention: Older children (4- and 5-year-olds)
Number of subjects: 3

Group type: COMPARATOR
Intervention: 3-year-olds
Number of subjects: 3
Study: 16434656

Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg for 4 weeks, then maintained or titrated to 5 or 20 mg at weeks 4 and 8)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 15726518

Group type: EXPERIMENTAL
Intervention: Amifostine (Ethyol; Medimmune Inc, Gaithersburg, MD) as a radiation protectant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11075309

Group type: EXPERIMENTAL
Intervention: Calcium citrate (Citracal 250 mg + D)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium carbonate (Os-Cal 500 mg + D)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9211023

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1543307

Group type: EXPERIMENTAL
Intervention: Semirecumbent position (45-degree angle)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 19
Study: 3987645

Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3359729

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29603513

Group type: EXPERIMENTAL
Intervention: Dementia risk score prediction model
Number of subjects: 27540
Study: 28496022

Group type: EXPERIMENTAL
Intervention: Azilsartan
Number of subjects: 64

Group type: COMPARATOR
Intervention: Olmesartan
Number of subjects: 64
Study: 26111932

Group type: EXPERIMENTAL
Intervention: CCRT + TME
Number of subjects: 184

Group type: COMPARATOR
Intervention: TME
Number of subjects: 184
Study: 23870381

Group type: EXPERIMENTAL
Intervention: Hep C nosode in 30c potency, once a week for four weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22